PDCD1 and non-small cell lung carcinoma: The monoclonal antibody targeting PD-1, nivolumab, could be used in the treatment of several advanced cancers, such as Hodgkin’s lymphoma, melanoma, NSCLC, RCC, squamous head and neck cancer and urothelial carcinoma (42).